DustyKat
Super Moderator
A paradigm in the evolution of care.
I have only quoted the opening paragraphs here. The article is a lengthy one so click on the source and you will find as you reach the end of the first page there are another 4 to follow.
It is well worth the read.
NOTE:Similar to when thiopurine drug monitoring was introduced in the early 2000s, physicians treating patients with inflammatory bowel disease are currently faced with a parallel question regarding how to choose the optimal dosing regimen for patients receiving biologics.
According to experts interviewed by Healio Gastroenterology, however, therapeutic drug monitoring of biologics is far more complex than with thiopurines, largely due to issues stemming from the development of antidrug antibodies that interfere with biologic activity.
Although the utilization of drug monitoring to provide tailored therapies with anti-tumor necrosis factor agents for patients with IBD is on the rise, lack of knowledge among clinicians, insufficient prospective data on outcomes and optimal therapeutic ranges, technological limitations of commercially available assays and cost issues continue to stand in the way of more widespread and optimized implementation. Despite these current barriers and uncertainties, experts said the growing body of evidence supports the rationale for clinicians to improve their understanding of factors that influence the pharmacokinetics of biologics and utilize therapeutic drug monitoring to optimize patient outcomes and reduce the costs of biologic therapies.
Source:
http://www.healio.com/gastroenterology/inflammatory-bowel-disease/news/print/healio-gastroenterology/%7B6eb50c6a-5504-4541-a420-3ffa003f5b40%7D/therapeutic-drug-monitoring-in-ibd
I have only quoted the opening paragraphs here. The article is a lengthy one so click on the source and you will find as you reach the end of the first page there are another 4 to follow.
It is well worth the read.